Nyxion Therapeutics (previously Bacto Therapeutics)

Nyxion Therapeutics is developing a bacterial-based therapeutic delivery platform for the treatment of hypoxic diseases. The venture aims to address the challenge of targeted and controlled in vivo delivery through the use of a genetically engineered bacteria designed to durably colonize hypoxic pathologies while secreting a range of therapeutic factors. The key differentiation lies in the platform's ability to produce novel combinations and sequences of factors to effectively mimic real complex physiological events. The result is a scalable, cost-effective, and tissue-specific technology, with unique potential to address critical unmet clinical needs across a range of hypoxic diseases including vascular diseases, oncology, infectious diseases and rare disease.